Drug Safety Data Curation and Modeling in ChEMBL: Boxed Warnings and Withdrawn Drugs

Use of Flecainide for the Treatment of Atrial Fibrillation

(2020) Debra S. Echt et al.   AMERICAN JOURNAL OF CARDIOLOGY

Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA

(2019) Leihong Wu et al.   BMC BIOINFORMATICS

An Overview of Machine Learning and Big Data for Drug Toxicity Evaluation

(2019) Andy H. Vo et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Machine learning-based identification and rule-based normalization of adverse drug reactions in drug labels

(2019) Mert Tiftikci et al.   BMC BIOINFORMATICS

A dataset of 200 structured product labels annotated for adverse drug reactions

(2018) Dina Demner-Fushman et al.   Scientific Data

Corrigendum: In Silico Prediction of Chemical Toxicity for Drug Design Using Machine Learning Methods and Structural Alerts

(2018) Hongbin Yang et al.   Frontiers in Chemistry

Predicting adverse drug reactions through interpretable deep learning framework

(2018) Sanjoy Dey et al.   BMC BIOINFORMATICS

Prediction of clinically relevant drug-induced liver injury from structure using machine learning

(2018) Felix Hammann et al.   JOURNAL OF APPLIED TOXICOLOGY

ChEMBL: towards direct deposition of bioassay data

(2018) David Mendez et al.   NUCLEIC ACIDS RESEARCH

New and incremental FDA black box warnings from 2008 to 2015

(2017) Michael T. Solotke et al.   Expert Opinion On Drug Safety

Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention

(2017) Peter A Henriksen   HEART

Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort

(2017) Abigail L Coughtrie et al.   BMJ Open

FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory science

(2016) Hong Fang et al.   DRUG DISCOVERY TODAY

Activity, assay and target data curation and quality in the ChEMBL database

(2015) George Papadatos et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making

(2014) Rhian McNaughton et al.   BMJ Open

Assessing bleeding risk in patients taking anticoagulants

(2013) Marwa Shoeb et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Quantitative Structure-Activity Relationship Models for Predicting Drug-Induced Liver Injury Based on FDA-Approved Drug Labeling Annotation and Using a Large Collection of Drugs

(2013) Minjun Chen et al.   TOXICOLOGICAL SCIENCES

ChEMBL: a large-scale bioactivity database for drug discovery

(2011) A. Gaulton et al.   NUCLEIC ACIDS RESEARCH

Market withdrawal of new molecular entities approved in the United States from 1980 to 2009

(2011) Zaina P. Qureshi et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY